Qualitative and quantitative detection of urinary human complement factor H-related protein (BTA stat and BTA TRAK) and fragments of cytokeratins 8, 18 (UBC rapid and UBC IRMA) as markers for transitional cell carcinoma of the bladder.
OBJECTIVE
To evaluate the role of BTA stat, BTA TRAK, UBC Rapid, UBC IRMA and voided urinary cytology in the detection of bladder transitional cell carcinoma (TCC).


METHODS
The study included 78 patients with TCC of the bladder (group A), 62 patients with a history of bladder TCC without tumor recurrence at the time of examination (B, control group), 20 patients with other malignancy of the urinary tract (C), 38 patients with non-malignant urinary tract diseases (D), 10 patients with urinary tract infection (E) and 10 healthy volunteers (F). Except in group F, voided urine was collected before cystoscopy or cystectomy.


RESULTS
The specificity and sensitivity in bladder cancer detection were 87.1 and 74.4%, respectively with BTA stat, 79.3 and 48.7%, respectively with UBC Rapid, 100 and 33.3%, respectively with cytology, 72.6 and 75.6%, respectively with BTA TRAK, 64.5 and 70.5%, respectively with UBC IRMA.


CONCLUSIONS
The BTA stat and BTATRAK tests are superior to UBC Rapid, UBC IRMA and urinary cytology in detection of bladder TCC. In daily practice however cytology remains the best adjunct to cystoscopy because of its high sensitivity in Tis and 100% specificity. Cystoscopy cannot be replaced by any of evaluated methods.
Babjuk
M
M
Department of Urology, General Teaching Hospital, 1st Medical Faculty, Charles University, Postgraduate Institute, Prague, Czech Republic. marko.babjuk@lf1.cuni.cz
Kostírová
M
M
Mudra
K
K
Pecher
S
S
Smolová
H
H
Pecen
L
L
Ibrahim
Z
Z
Dvorácek
J
J
Jarolím
L
L
Novák
J
J
Zima
T
T
D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000652:urine*; D014408:Biomarkers, Tumor / Q000652:urine*; D002295:Carcinoma, Transitional Cell / Q000175:diagnosis* / Q000652:urine; D017242:Complement Factor H / Q000652:urine*; D003558:Cystoscopy; D005260:Female; D006801:Humans; D007633:Keratins / Q000652:urine*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D012494:Sampling Studies; D012680:Sensitivity and Specificity; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis* / Q000652:urine
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; C493495:CFH protein, human; C112999:bladder tumor-associated antigen; D007633:Keratins; D017242:Complement Factor H